27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Atossa Therapeutics Inc (NASDAQ: ATOS) announces final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19.
- The treatment was considered to be safe and well-tolerated at two different dose levels over 14 days.
- The final analysis indicates that there were no serious adverse events, no discontinuations, no bronchospasm.
- Only one of the 32 subjects in the study experienced moderate adverse events, and all other adverse events were considered mild.
- An additional pre-clinical study is expected to start this quarter.
- Price Action: ATOS surged 8.6% at $3.02 on the last check Thursday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!